Home›Drug Pipeline› Dihydromyricetin improves lipid profiles, liver enzymes, and glucose in preclinical NAFLD models
Dihydromyricetin improves lipid profiles, liver enzymes, and glucose in preclinical NAFLD modelsDihydromyricetin Shows Potential for Managing Fatty Liver Disease
Frontiers in MedicinePublished August 24, 2026DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider DHM as a promising preclinical agent for NAFLD, but await human data before clinical use.
This is a meta-analysis of preclinical studies evaluating the pharmacological effects of dihydromyricetin (DHM) in animal models of nonalcoholic fatty liver disease (NAFLD). The analysis included 13 studies encompassing 14 independent experiments with a total of 316 animals. The primary outcome was the pharmacological effect of DHM on NAFLD, with secondary outcomes focusing on hepatic and serum lipid profiles, liver enzyme levels, and glucose homeostasis.
The pooled findings indicate that DHM improved hepatic and serum lipid profiles, liver enzyme levels, and glucose homeostasis in these animal models. Notably, lipid-related outcomes appeared more sensitive to dose, while liver enzyme improvements were more responsive to treatment duration. However, no effect sizes, confidence intervals, or p-values were reported, and the comparator was not specified.
The authors noted high heterogeneity across all strata, even after subgroup analyses, which limits the precision of the conclusions. Adverse events, tolerability, and follow-up duration were not reported. As this is a preclinical meta-analysis, the results should be interpreted with caution; animal model findings may not translate to human NAFLD.
In practice, DHM shows promise as a potential therapeutic agent for NAFLD, but further research, including well-designed human trials, is needed to confirm efficacy and safety. Clinicians should not extrapolate these preclinical results to patient care at this time.
Researchers analyzed 13 studies involving 316 animals to see how a compound called dihydromyricetin (DHM) affects non-alcoholic fatty liver disease (NAFLD). The study looked at several markers, including liver enzymes, blood sugar levels, and lipid profiles. The findings showed that DHM led to improvements in these areas across the animal models tested.
The results were more noticeable when the treatment lasted longer or when higher doses were used. These improvements suggest that the compound may have helpful pharmacological effects for liver health. However, it is important to note that this research was conducted entirely on animals rather than in humans.
Because these findings come from preclinical animal models, they do not confirm how the compound will work in people. There was also a high level of variation across the different studies analyzed. These results are early and should be viewed as a starting point for future research into liver health treatments.
What this means for you:
Early animal studies show dihydromyricetin may improve liver markers, but human results are not yet known.
Common questions
What is dihydromyricetin?
Dihydromyricetin (DHM) is a compound that was tested in this study to see its effects on non-alcoholic fatty liver disease. The research looked at how it impacts liver enzymes, blood sugar levels, and lipid profiles in animal models.
Can dihydromyricetin treat fatty liver disease in humans?
The current evidence comes only from preclinical studies using animal models. Because these results were not tested in humans, it is not yet known if the compound is effective or safe for people with fatty liver disease.
What specific improvements were seen in the study?
The analysis of 13 studies showed that dihydromyricetin improved hepatic and serum lipid profiles, liver enzyme levels, and glucose homeostasis. These improvements were more noticeable when the treatment duration was longer or doses were higher.
BackgroundDihydromyricetin (DHM), a naturally occurring flavonoid, has shown beneficial effects in preclinical models of non-alcoholic fatty liver disease (NAFLD). Nevertheless, the extent to which dose and treatment duration influence its pharmacological effects remains to be systematically evaluated.ObjectiveThis study aimed to evaluate the pharmacological effects of DHM in preclinical models of NAFLD and to further explore the potential influence of treatment dose and duration on these effects using subgroup analyses.MethodsStudies were identified through systematic searches of six electronic databases. Eligible animal studies were included according to predefined criteria. Risk of bias (RoB) was assessed using the SYRCLE tool. Quantitative synthesis was performed using RevMan (version 5.4). To further explore the potential influence of treatment dose and duration, three-dimensional (3D) visualization plots and radar charts were generated using OriginPro 2024.ResultsA total of 13 studies encompassing 14 independent experiments with 316 animals were included. DHM was associated with improvements in hepatic and serum lipid profiles, liver enzyme levels, and glucose homeostasis. Heterogeneity remained high across strata despite subgroup analyses by dose and duration. Integrated 3D plots and radar charts visually illustrated these findings.ConclusionDHM exhibited favorable pharmacological effects in preclinical models of NAFLD, with lipid-related outcomes appearing more sensitive to dose and liver enzyme outcomes showing greater responsiveness to treatment duration. Persistent heterogeneity highlights the need for standardized experimental protocols in future preclinical research.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420251124831, identifier CRD420251124831.
